<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03921528</url>
  </required_header>
  <id_info>
    <org_study_id>SRK-015-002</org_study_id>
    <nct_id>NCT03921528</nct_id>
  </id_info>
  <brief_title>An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy</brief_title>
  <acronym>TOPAZ</acronym>
  <official_title>Phase 2 Active Treatment Study to Evaluate the Efficacy and Safety of SRK-015 in Patients With Later-Onset Spinal Muscular Atrophy (TOPAZ)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scholar Rock, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scholar Rock, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The TOPAZ study will assess the safety and efficacy of SRK-015 in later-onset Spinal Muscular&#xD;
      Atrophy (SMA Type 2 and Type 3) in pediatric and adult patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 22, 2019</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Actual">January 12, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Active treatment, randomized, double-blind for Cohort 3</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort 1: Change from Baseline in the Revised Hammersmith Scale (RHS)</measure>
    <time_frame>Baseline up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 2 and Cohort 3: Change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE)</measure>
    <time_frame>Baseline up to 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Spinal Muscular Atrophy</condition>
  <condition>Spinal Muscular Atrophy Type 3</condition>
  <condition>Spinal Muscular Atrophy Type 2</condition>
  <condition>SMA</condition>
  <condition>Neuromuscular Diseases</condition>
  <condition>Muscular Atrophy</condition>
  <condition>Atrophy</condition>
  <condition>Muscular Atrophy, Spinal</condition>
  <condition>Neuromuscular Manifestations</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ambulatory Type 3 SMA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Type 2 SMA / Non-Ambulatory Type 3 SMA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Type 2 SMA</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SRK-015</intervention_name>
    <description>SRK-015 is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that binds to human pro/latent myostatin with high affinity. SRK-015 will be administered every 4 weeks by intravenous infusion.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 5 through 21 years old at the time of screening for Cohorts 1 and 2; Age ≥2 years&#xD;
             old at the time of screening for Cohort 3.&#xD;
&#xD;
          -  Documented diagnosis of 5q SMA.&#xD;
&#xD;
          -  Diagnosed as later-onset (e.g., Type 2 or Type 3) SMA prior to receiving any treatment&#xD;
             with therapy approved for SMA.&#xD;
&#xD;
          -  Non-ambulatory patients must be able to sit independently (sits up straight with head&#xD;
             erect for at least 10 seconds; does not use arms or hands to balance body or support&#xD;
             position) per World Health Organization (WHO) motor milestones definition at&#xD;
             screening.&#xD;
&#xD;
          -  Ambulatory patients must have the ability to independently ambulate without aids or&#xD;
             orthotics over 10 meters in 30 seconds or less at screening.&#xD;
&#xD;
          -  Receiving the same background SMA therapy (e.g., on an approved survival motor neuron&#xD;
             (SMN) upregulator therapy such as nusinersen, or not on any SMA therapy) for at least&#xD;
             6 months prior to screening and anticipated to remain on that therapy throughout the&#xD;
             duration of the study.&#xD;
&#xD;
               -  If receiving the SMN upregulator therapy nusinersen, must have completed the&#xD;
                  loading regimen and initiated maintenance dosing (i.e., completed at least one&#xD;
                  maintenance dose) with at least 4 weeks after the first maintenance dose having&#xD;
                  elapsed prior to screening.&#xD;
&#xD;
          -  Nutritional status stable over the past 6 months and anticipated to be stable&#xD;
             throughout the duration of the study.&#xD;
&#xD;
          -  Have no physical limitations that would prevent the patient from undergoing motor&#xD;
             function outcome measures throughout the duration of the study.&#xD;
&#xD;
          -  Able to receive study drug infusions and provide blood samples through the use of a&#xD;
             peripheral intravenous (IV) or a long-term IV access device that the patient has&#xD;
             placed for reasons independent from the study throughout the duration of the study.&#xD;
&#xD;
          -  Able to adhere to the requirements of the protocol, including travel to the study&#xD;
             center and completing all study procedures and study visits.&#xD;
&#xD;
          -  For patients who are expected to have reached reproductive maturity by the end of the&#xD;
             study, adhere to study specific contraception requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of tracheostomy with positive pressure.&#xD;
&#xD;
          -  Use of chronic daytime non-invasive ventilatory support for &gt;16 hours daily in the 2&#xD;
             weeks prior to dosing, or anticipated to regularly receive such daytime ventilator&#xD;
             support chronically over the duration of the study.&#xD;
&#xD;
          -  Any acute or co-morbid condition interfering with the well-being of the patient within&#xD;
             14 days of screening, including active systemic infection, the need for acute&#xD;
             treatment or inpatient observation due to any reason.&#xD;
&#xD;
          -  Severe scoliosis and/or contractures at screening. Based on clinical judgement, any&#xD;
             scoliosis or contractures present must be stable over the past 6 months, anticipated&#xD;
             to be stable for the duration of the study and not prevent the patient from being&#xD;
             evaluated on any functional outcome measures throughout the duration of the study.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Major orthopedic or other interventional procedure, including spine or hip surgery,&#xD;
             considered to have the potential to substantially limit the ability of the patient to&#xD;
             be evaluated on any functional outcome measures, within 6 months prior to screening,&#xD;
             or anticipated for the duration of the study.&#xD;
&#xD;
          -  Prior history of a hypersensitivity reaction to a monoclonal antibody (mAb) or&#xD;
             recombinant protein bearing an Fc domain (such as a soluble receptor- Fc fusion&#xD;
             protein).&#xD;
&#xD;
          -  Use of systemic corticosteroids within 60 days prior to screening. Inhaled or topical&#xD;
             steroids are allowed.&#xD;
&#xD;
          -  Treatment with investigational drugs within 3 months prior to screening.&#xD;
&#xD;
          -  Use of therapies with potentially significant muscle effects (such as androgens,&#xD;
             insulin-like growth factor, growth hormone, systemic betaagonist, botulinum toxin, or&#xD;
             muscle relaxants) or muscle-enhancing supplements within 60 days prior to screening.&#xD;
&#xD;
          -  Patient has any other condition, which in the opinion of the Investigator may&#xD;
             compromise safety or compliance, would preclude the patient from successful completion&#xD;
             of the study, or interfere with the interpretation of the results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas O. Crawford, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Clinico Nemo Pediatrico Policlinico A. Gemelli-Università Cattolica Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2019</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Neuromuscular Diseases</mesh_term>
    <mesh_term>Spinal Muscular Atrophies of Childhood</mesh_term>
    <mesh_term>Neuromuscular Manifestations</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

